- Home
- NNBR vs PLRX Comparison
NNBR vs PLRX Comparison
Compare NNBR & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NNBR | PLRX |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 79.9M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NNBR | PLRX |
|---|---|---|
| Price | $1.24 | $1.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $3.00 | $2.67 |
| AVG Volume (30 Days) | 212.4K | ★ 609.4K |
| Earning Date | 06-12-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.60 | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $770,657,000.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.09 |
| 52 Week High | $2.67 | $1.95 |
Technical Indicators
Market Signals| Indicator | NNBR | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.95 | 57.06 |
| Support Level | $1.20 | $1.12 |
| Resistance Level | $1.43 | $1.36 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 6.17 | 58.54 |
Price Performance
Historical ComparisonAbout NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.